Keyphrases
Clinical Significance
100%
Dosimetry
100%
Radioimmunotherapy
100%
Tositumomab
100%
Iodine
100%
I-131
100%
Tumor
33%
Patient-specific
33%
Residence Time
33%
Radionuclides
22%
Total-body
22%
Clearance Rate
22%
Dosimetric
22%
Clinical Trials
11%
Targeted Therapy
11%
Targeted Drugs
11%
Non-Hodgkin Lymphoma
11%
Radiation Dose
11%
Therapeutic Agents
11%
Radioactivity
11%
Therapeutic Effect
11%
Drug Levels
11%
Iodine-131 (131I)
11%
Whole-body Dosimetry
11%
Patient-specific Dose
11%
San Francisco
11%
Inter-patient Variability
11%
Two-level
11%
Beta Particles
11%
Gamma Photon
11%
Philadelphia
11%
Therapeutic Radiation
11%
Emerging Therapies
11%
GlaxoSmithKline
11%
Radioimmunoconjugate
11%
Bexxar
11%
Bone Marrow Toxicity
11%
Medicine and Dentistry
Iodine 131
100%
Dosimetry
100%
Radioimmunotherapy
100%
Tositumomab I 131
100%
Tositumomab
100%
Neoplasm
50%
Radioisotope
33%
Clinical Trial
16%
Targeted Therapy
16%
Non-Hodgkin Lymphoma
16%
Therapy Effect
16%
Bone Marrow Toxicity
16%
Radiation Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Dosimetry
100%
Iodine-131
100%
Tositumomab
100%
Tositumomab I 131
100%
Neoplasm
50%
Radioisotope
33%
Clinical Trial
16%
Nonhodgkin Lymphoma
16%
Therapeutic Effect
16%
Bone Marrow Toxicity
16%